Zobrazeno 1 - 10
of 235
pro vyhledávání: '"Jan, Dürig"'
Autor:
Jan Dürig, Jens Uhlig, Anke Gerhardt, Markus Ritter, Gunnar Hapke, Jörg Heßling, Peter Staib, Frieder Wolff, Katja Krumm, Ludwig Fischer vonWeikersthal
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2739-2751 (2023)
Abstract Background Rituximab has become a standard treatment for non‐Hodgkin lymphoma. Clinical studies have demonstrated the efficacy of rituximab in combination with standard chemotherapies in the treatment of follicular lymphoma (FL) and diffus
Externí odkaz:
https://doaj.org/article/39f98f0edd424b1abc4ef74d4c24f12b
Autor:
Patricia Johansson, Teresa Laguna, Julio Ossowski, Vera Pancaldi, Martina Brauser, Ulrich Dührsen, Lara Keuneke, Ana Queiros, Julia Richter, José I. Martín-Subero, Reiner Siebert, Brigitte Schlegelberger, Ralf Küppers, Jan Dürig, Eva M. Murga Penas, Enrique Carrillo-de Santa Pau, Anke K. Bergmann
Publikováno v:
Clinical Epigenetics, Vol 15, Iss 1, Pp 1-3 (2023)
Externí odkaz:
https://doaj.org/article/1e6999907c254d8d9ce9c8c4662b15aa
Autor:
Lisa Baak, Mirjam Frank, Jan Dürig, Ulrich Dührsen, Per Hoffmann, Markus M. Nöthen, Nico Dragano, Raimund Erbel, Karl-Heinz Jöckel, Börge Schmidt
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Environmental, genetic, and social factors are suggested to jointly influence monoclonal gammopathy of undetermined significance (MGUS), a precursor of multiple myeloma. Aim of this study was to investigate interactions between MGUS-related
Externí odkaz:
https://doaj.org/article/4d3a4745ce41494ab47ffb8c4d51b698
Autor:
Nicola Hornung, Mirjam Frank, Nico Dragano, Jan Dürig, Ulrich Dührsen, Susanne Moebus, Raimund Erbel, Andreas Stang, Karl-Heinz Jöckel, Börge Schmidt
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract Register-based studies indicate a possible association of monoclonal gammopathy of undetermined significance (MGUS) and prostate cancer (PCa). Aim of the present study was to investigate the relationship between MGUS and PCa considering pote
Externí odkaz:
https://doaj.org/article/1bb8b1a1b42b48c58cbe6c46ed57d06b
Autor:
Marc-Andrea Baertsch, Elias K. Mai, Thomas Hielscher, Uta Bertsch, Hans J. Salwender, Markus Munder, Stephan Fuhrmann, Ulrich Dührsen, Peter Brossart, Kai Neben, Jana Schlenzka, Christina Kunz, Marc S. Raab, Jens Hillengaß, Anna Jauch, Anja Seckinger, Dirk Hose, Steffen Luntz, Pieter Sonneveld, Henk Lokhorst, Hans Martin, Martin Goerner, Martin Hoffmann, Hans-Walter Lindemann, Helga Bernhard, Igor W. Blau, Christof Scheid, Britta Besemer, Katja C. Weisel, Mathias Hänel, Jan Dürig, Hartmut Goldschmidt, German-Speaking Myeloma Multicenter Group (GMMG)
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared borte
Externí odkaz:
https://doaj.org/article/c1262202ec704fb3bc2b8009125681e4
Autor:
Laila König, Martin Dreyling, Jan Dürig, Marianne Engelhard, Karin Hohloch, Andreas Viardot, Mathias Witzens-Harig, Meinhard Kieser, Wolfram Klapper, Christiane Pott, Klaus Herfarth
Publikováno v:
Trials, Vol 20, Iss 1, Pp 1-8 (2019)
Abstract Background Large field irradiation had been standard for early-stage follicular lymphoma (FL) for a long time. Although involved field radiotherapy (IF-RT) was recently favored because of the toxicity of large field irradiation, smaller irra
Externí odkaz:
https://doaj.org/article/4257a87c396748f6be1659d0dc328543
Autor:
Katharina Kriegsmann, Calin Manta, Ricarda Schwab, Elias K. Mai, Marc S. Raab, Hans J. Salwender, Roland Fenk, Britta Besemer, Jan Dürig, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Anne M. Asemissen, Bernhard Heilmeier, Uta Bertsch, Stefanie Huhn, Carsten Müller-Tidow, Hartmut Goldschmidt, Michael Hundemer
Publikováno v:
Blood Advances. 7:379-383
CA extern
Autor:
Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, Roland Fenk, Eva Nievergall, Diana Tichy, Britta Besemer, Jan Dürig, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Anne M Asemissen, Bernhard Heilmeier, Niels Weinhold, Stefanie Huhn, Katharina Kriegsmann, Steffen P Luntz, Tobias A W Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Müller, Cyrus Khandanpour, Wolfgang Knauf, Christof Scheid, Markus Munder, Thomas Geer, Hendrik Riesenberg, Jörg Thomalla, Martin Hoffmann, Marc S Raab, Hans J Salwender, Katja C Weisel, Joachim Behringer, Helga Bernhard, Christiane Bernhardt, Igor W Blau, Claus Bolling, Daniel Debatin, Gerrit Dingeldein, Barbara Ferstl, Claudia Fest, Stefan Fronhoffs, Stephan Fuhrmann, Tobias Gaska, Martin Görner, Ullrich Graeven, Jochen Grassinger, Michael Heinsch, Gerhard Held, Olaf Hopfer, Peter Immenschuh, Dominic Kaddu-Mulindwa, Martine Klausmann, Stefan Klein, Yon-Dschun Ko, Georg Köchling, Michael Koenigsmann, Philippe Kostrewa, Doris Maria Kraemer, Stephan Kremers, Martin Kropff, Paul La Rosée, Rolf Mahlberg, Uwe Martens, Michael Neise, Holger Nückel, Wolfram Pönisch, Maria Procaccianti, Mohammed R Rafiyan, Peter Reimer, Armin Riecke, Mathias Rummel, Volker Runde, Markus Schaich, Christoph Scheid, Martin Schmidt-Hieber, Stefan Schmitt, Daniel Schöndube, Andreas Schwarzer, Peter Staib, Heike Steiniger, Dirk Sturmberg, Hans-Joachim Tischler, Arne Trummer, Barbara Tschechne, Walter Verbeek, Bettina Whitlock, Maike de Wit, Matthias Zaiß, Carsten Ziske
Publikováno v:
The Lancet Haematology. 9:e810-e821
Anti-CD38 monoclonal antibodies have consistently shown increased efficacy when added to standard of care for patients with multiple myeloma. We aimed to assess the efficacy of isatuximab in addition to lenalidomide, bortezomib, and dexamethasone in
Autor:
Patricia Johansson, Laura Dierichs, Ludger Klein-Hitpass, Anke K. Bergmann, Michael Möllmann, Sascha Menninger, Peter Habenberger, Bert Klebl, Jens T. Siveke, Ulrich Dührsen, Axel Choidas, Jan Dürig
Publikováno v:
Therapeutic Advances in Hematology, Vol 11 (2020)
T-cell prolymphocytic leukemia (T-PLL) is an aggressive malignancy characterized by chemotherapy resistance and a median survival of less than 2 years. Here, we investigated the pharmacological effects of the novel highly specific cyclin-dependent ki
Externí odkaz:
https://doaj.org/article/dbaad95c53fa476da2bd0fedf8b2e735
Autor:
Paula Cramer, Julia v. Tresckow, Sandra Robrecht, Jasmin Bahlo, Moritz Fürstenau, Petra Langerbeins, Natali Pflug, Othman Al-Sawaf, Werner J. Heinz, Ursula Vehling-Kaiser, Jan Dürig, Eugen Tausch, Manfred Hensel, Stephanie Sasse, Anna-Maria Fink, Kirsten Fischer, Karl-Anton Kreuzer, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Clemens-Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Publikováno v:
Haematologica, Vol 106, Iss 2 (2020)
The introduction of targeted agents has revolutionized the treatment of chronic lymphocytic leukemia but only few patients achieve complete remissions and minimal residual disease negativity with ibrutinib monotherapy. This multicenter, investigator-
Externí odkaz:
https://doaj.org/article/2ca066e2adef4fddaa1e0e1cd1ae9f54